871555-75-8

Usage

Uses

Used in Pesticide Industry:
Carbamic acid, N-[4-chloro-3-(trifluoromethyl)phenyl]-, phenyl ester is used as an active ingredient for the development of herbicides and pesticides. It is valued for its bioactive properties that contribute to the control of unwanted plants and pests, ensuring the protection and growth of crops.
Used in Herbicide Formulation:
Carbamic acid, N-[4-chloro-3-(trifluoromethyl)phenyl]-, phenyl ester is used as a key component in the formulation of herbicides. Its effectiveness in controlling a wide range of weeds makes it a popular choice for agricultural applications, helping to maintain healthy and productive crop fields.
It is important to handle Carbamic acid, N-[4-chloro-3-(trifluoromethyl)phenyl]-, phenyl ester with caution due to its potential implications on human health and the environment. Proper safety measures and regulations should be followed to minimize any adverse effects.

Upstream product

• 1885-14-9 phenyl chloroformate 
• 320-51-4 4-chloro-3-trifluoromethyl-aniline 

Downstream Products

• 1129683-83-5 4-[ ({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenol 
• 284461-73-0 sorafenib 
• 1012058-78-4 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-pyridinecarboxylic acid 

Relevant academic research and scientific papers

Discovery and Mechanism of Action of Small Molecule Inhibitors of Ceramidases**

Sphingolipid metabolism is tightly controlled by enzymes to regulate essential processes in human physiology. The central metabolite is ceramide, a pro-apoptotic lipid catabolized by ceramidase enzymes to produce pro-proliferative sphingosine-1-phosphate. Alkaline ceramidases are transmembrane enzymes that recently attracted attention for drug development in fatty liver diseases. However, due to their hydrophobic nature, no specific small molecule inhibitors have been reported. We present the discovery and mechanism of action of the first drug-like inhibitors of alkaline ceramidase 3 (ACER3). In particular, we chemically engineered novel fluorescent ceramide substrates enabling screening of large compound libraries and characterized enzyme:inhibitor interactions using mass spectrometry and MD simulations. In addition to revealing a new paradigm for inhibition of lipid metabolising enzymes with non-lipidic small molecules, our data lay the ground for targeting ACER3 in drug discovery efforts.

Crystal form of medicine for treating intestinal cancer

The invention relates to a crystal form of a medicine for treating intestinal cancer. The crystal form with high purity and low impurity content is obtained, and a preparation process with low technical expenditure and high yield is provided.

Design, synthesis, and biological evaluation of sorafenib derivatives containing indole (ketone) semicarbazide analogs as antitumor agents

A series of new sorafenib derivatives was designed and synthesized. The antiproliferative activity of the synthesized compounds against human lung cancer cell (A549), human pancreatic cancer cell (PC-3), human leukemia cell (K562), and human hepatoma cell (SMMC-7721) was evaluated by MTT assay. The results revealed that several compounds displayed more significant antitumor activities than commercial anticancer agent sorafenib against SMMC-7721. In addition, compounds 7a, 7g, 7l, 7m, and 7p represented obvious growth inhibition with IC50 values of 1-9 μM against four cancer cell lines, demonstrating more predominant activities against cancer cells as compared to sorafenib. Furthermore, some structure-activity relationships have also been established. Compounds containing indole and benzene ring substituted by halogen showed better activity than sorafenib. Wound healing assay suggested that cells would be targeted on their migratory capacity by 7g, potentially affecting the migration activity of these tumors. The effects of A549 and PC-3 cell apoptosis induced by compound 7g were significantly increased compared with sorafenib. Importantly, the result of western blot assay showed that 7g inhibited cell growth by suppressing the activity of EGFR, especially the expression of p-EGFR (Tyr1068).

RAF-DEGRADING CONJUGATE COMPOUNDS

The present disclosure provides, inter alia, RAF-Degrading Conjugate Compounds that are useful in the treatment of cancer and other RAF related diseases. Also provided are, pharmaceutical compositions, methods of treatment, and kits comprising a RAF- Degrading Conjugate Compound.

Medicinal preparation for treating intestinal cancer

The invention discloses a medicinal preparation for treating intestinal cancer. According to the medicinal preparation for treating the intestinal cancer, 4-[4-({[4-CI-3(trichloromethyl)phenyl]carbamyl}amidogen)-3,5-difluorobenzoxy]-N-picoline-2-formamide is adopted as a new active pharmaceutical ingredient, medical auxiliary materials comprise a filling agent, a disintegrating agent, a bonding agent and a lubricating agent. The medicinal preparation is prepared into tablets by adopting a simple pelleting way, significant effects are shown in treatment of a colorectal cancer disease, disintegrating and dissolving of similar medication are relieved, the bioavailability of medication is improved, and the safety is improved.

Compounds for curing intestinal cancers

The invention relates to compounds for curing intestinal cancers. The compounds are obtained by the following steps: 4-chloro-3-(trifluoromethyl)aniline and phenyl chloroformate are subjected to amidation reaction, thus an intermediate is obtained, the obtained intermediate and 4-amino-difluorophenol are subjected to amidation reaction, thus an intermediate is obtained, the obtained intermediate and 4-chloro-N-methyl-2-pyridinecarboxamide are subjected to alkylation reaction, thus an intermediate is obtained, and the obtained intermediate is subjected to salt forming reaction, so that the objective compounds of a general formula shown in the description are obtained. The objective compounds which have the general formula can be used for curing intestinal cancers.

NOVEL QUINOLINE DERIVATIVES AND THEIR APPLICATIONS

The invention relates to a series of quinoline derivatives of general formula I, pharmaceutically acceptable salts, hydrates, solvates or prodrugs. Thereof M, R1, R2, X, Y and n are defined as claims. And the compounds of general formula I show potent inhibitory activity against c-Met kinase. The present invention further relates to the uses of the compounds, pharmaceutically acceptable salts and hydrates for the preparation of medicaments for the treatment and/or prevention of diseases caused by abnormal expression of c-Met kinase, especially for treatment and/or prevention of cancer.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

CYCLOPROPANECARBOXAMIDO-SUBSTITUTE AROMATIC COMPOUNDS AS ANTI-TUMOR AGENTS

Provided are cyclopropanecarboxamido-substituted aromatic compounds that inhibit protein kinases and their use in anti-tumor area. In particular, tyrosine-kinase inhibitors and Raf-kinase inhibitors as anti-tumor agents, their preparation, pharmaceutical composition, and their use in the treatment of cancer are also provided.

PREPARATION METHOD OF FLUORO-SUBSTITUTED DEUTERATED DIPHENYLUREA

A fluoro-substituted deuterated diphenylurea compound, especially 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-(N-(methyl-d3))picolinamide, preparing method and use for treating or preventing tumor and relative diseases thereof.